V
Viking Therapeutics, Inc. (VKTX)
NCM – Real Time Price. Currency in USD
32.52
-1.73 (-5.05%)
At close: Mar 27, 2026, 4:00 PM EDT
32.49
-0.03 (-0.09%)
After-hours: Mar 27, 2026, 7:57 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
32.52
-1.73 (-5.05%)
At close: Mar 27, 2026, 4:00 PM EDT
32.49
-0.03 (-0.09%)
After-hours: Mar 27, 2026, 7:57 PM EDT
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Brian Lian Ph.D. | President, CEO & Director |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gregory S. Zante CPA | Chief Financial Officer |
| Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales |
| Mr. Michael Morneau | Vice President of Finance & Administration |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
| Ms. Marianne Mancini | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2025-10-23 | 10-Q | vktx-20250930.htm |
| 2025-10-22 | 8-K | vktx-20251022.htm |
| 2025-08-19 | 8-K | vktx-20250819.htm |
| 2025-07-23 | 8-K | vktx-20250723.htm |
| 2025-05-27 | 8-K | vktx-20250520.htm |
| 2025-04-24 | 10-Q | vktx-20250331.htm |
| 2025-04-23 | 8-K | vktx-20250423.htm |
| 2025-04-08 | ARS | vktx-2025-04-07-ars_v2.pdf |
| 2025-03-11 | 8-K | vktx-20250310.htm |
| 2025-02-26 | 10-K | vktx-20241231.htm |